DOCSLIB.ORG

United States Patent (19) (11 Patent Number: 4,749,575 Rotman 45 Date of Patent: Jun

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) (11 Patent Number: 4,749,575 Rotman 45 Date of Patent: Jun United States Patent (19) (11 Patent Number: 4,749,575 Rotman 45 Date of Patent: Jun. 7, 1988 54 MICROENCAPSULATEDMEDICAMENT IN 4,327,077 8/1982 Puglia et al. .......................... 424/38 SWEET MATRIX 4,490,352 12/1984 Miller ............. ... 424/17 4,543,262 9/1985 Michnowski. ... 426/72 75) Inventor: Avner Rotman, Rehovot, Israel 4,587,118 5/1986 Hsiao ..................................... 424/19 73) Assignee: Bio-Dar Ltd., Rehovot, Israel FOREIGN PATENT DOCUMENTS 21) Appl. No.: 823,798 90.0749A 2/1985 Belgium . 3435747A 4/1985 Fed. Rep. of Germany . (22 Filed: Jan. 29, 1986 717369 1/1932 France .................................. 424/17 68083 3/1958 France .................................. 424/17 Related U.S. Application Data 2496403 6/1982 France .................................. 424/7 63 Continuation-in-part of Ser. No. 538,801, Oct. 3, 1983, 2552665 4/1985 France. abandoned. 164102 12/1981 Japan .................. ... 424/17 46901 3/1982 Japan ...... ... 424/17 51) Int. Cl* .......................... A61K 9/22; A61K9/52 13503 1/1983 Japan ..................................... 424/7 52 U.S. C. ................................... 424/441; 424/440; 60-94058 5/1985 Japan . 424/457; 424/468; 424/490 102138A 6/1985 Japan . 58) Field of Search ............... 426/616, 613, 631, 660, 8403003 5/1985 Netherlands . 519858 4/1972 Switzerland . 426/572, 72, 74; 424/22, 48, 17, 440, 490, 457, 875763 8/1961 United Kingdom . 468, 441; 514/777 1297221 11/1972 United Kingdom . (56) References Cited 1342.974 1/1974 United Kingdom . 1439240 6/1976 United Kingdom . U.S. PATENT DOCUMENTS 2057847 4/1981 United Kingdom . 2,538,202 1/1951 Kimball ................................. 426/74. 1598458 9/1981 United Kingdom . 2,634,210 4/1953 Kimball ................................. 426/72 2092425 8/1982 United Kingdom . 2,957,804 10/1960 Shuyler ................................. 424/17 2147501A 5/1985 United Kingdom . 3,520,970 7/1970 Lehmann et al. ..................... 424/25 3,697,641 10/1972. Ahrens ................. 426/72 OTHER PUBLICATIONS 3,775,537 11/1973 Lehmann et al..... 424/21 Chemical Abstracts, 78-151637 (1973). 3,814,819 6/1974 Morgan ................ 426/72 3,821,422 6/1974 Morse et al. ..... 426/72 Derwent Abstract of Rotman-V, Belgium 900749-A 3,835,221 9/1974 Fulberth et al. 424/20 (01-02-85), Australian Patent Abstract of Rotman-VI 3,860,733 1/1975 Morse et al. ......... ... 426/302 -AV-A-33799184 (18-4–85). 3,954,959 5/1976 Pedersen ............................... 424/21 Lockman et al., "The Theory & Practice of Indust. 3,962,416 6/1976 Katzen .................................. 426/74 Pharmy, 2nd Ed., Lea & Febiger, 1976, p. 420. 3,992,555 11/1976 Kovacs ................................. 426/72 Chem Abstracts 98:70502N, "Stability of Food Forti 3,992,556 11/1976 Kovacs ................................. 426/72 4,000,322 12/1976 Billerbeck et al. .................... 426/72 fied with Vit. A microcapsules, (1983), Li et al. 4,018,900 4/1977 Hayward et al..... 426/72 Primary Examiner-Shep K. Rose 4,018,901 4/1977 Hayward et al. ... 426/72 Attorney, Agent, or Firm-Browdy and Neimark 4,038,423 7/1977 Hayward et al. ... 426/72 4,049,832 9/1977 Hayward et al..... 426/72 57 ABSTRACT 4,062,986 12/1977 Billerbeck et al. ... 426/72 4,083,949 4/1978 Benedikt .............. 424/19 Any orally administrable medicament is prepared into a 4,101,651 7/1978 Kobayashi et al 424/35 dosage form which eliminates the unpleasant taste and 4,102,806 7/1978 Kondo et al. ........ 426/72 mouth feel of the medicament and is easily and pleas 4,152,462 5/1979 Hayward et al. 426/72 antly ingested even by children, by microencapsulating 4,153,735 5/1979 Mommer .......... 426/72 4,182,778 1/1980 Hall et al. ... 426/72 the medicament into microcapsules of less than 300 4,191,783 3/1980 Burkwall ...... 426/72 microns diameter, and embedding the microcapsules 4,230,687 10/1980 Sair et al. ..... 426/72 into a soft, sweet, palatable matrix, such as chocolate. 4,271,142 6/1981 Puglia et al. ... 424/14 4,284,652 8/1981 Christenson .......................... 426/72 10 Claims, No Drawings 4,749,575 1. 2 breakage of any substantial number of microcapsules in MICROENCAPSULATED MEDICAMENT IN the mouth might create an overdose condition. SWEET MATRIX It has been known to fortify food, including candies, with encapsulated vitamins. This was done to fortify the CROSS-REFERENCE TO RELATED 5 food rather than provide an improved dosage mode of APPLICATION administration of the vitamin. The present invention is a continuation-in-part of application Ser. No. 538,801, filed Oct. 3, 1983, now SUMMARY OF THE INVENTION abandoned the entire contents of which are hereby Accordingly, it is an object of the present invention incorporated by reference. 10 to provide a new form of medication for oral adminis tration. FIELD OF THE INVENTION It is another object of the present invention to pro The present invention relates to a manner in which vide a new form of medicament for oral administration medicaments may be orally administered to children or in which the unpalatable taste and mouth feel of the others in a pleasant manner in which the taste of the 15 medicament is totally eliminated. medicament is totally hidden. More particularly, the It is a further object of the present invention to pro present invention relates to a medicament form for per vide a new form of medicament which is very palatable mitting such administration. to children, as well as adults. BACKGROUND OF THE INVENTION It is still a further object of the present invention to Oral medication is one of the most popular methods provide a form of medicament which is chewed and of drug administration into the body because it enables swallowed by the patient without substantial release of self-medication of the patient. In this category, palat the medicament into the mouth during the chewing ability is an extremely important factor in formulating process. pharmaceutical forms. Because of the strong unpleasant 25 It is yet a further object of the present invention to taste of many medicaments, the value of many drugs is provide a new form of medicament which may be substantially diminished. This is particularly common chewed and swallowed as a solid but in which the medi among children's medications, but is also true for adults. cament passes through the stomach without release In order to overcome these problems of unpleasant taste until reaching the intestines. and unpalatable taste, many flavorings have been em 30 It is still another object of the present invention to ployed with pharmaceuticals. Thus, it is very common provide a chewable sustained release medicament. to administer many children's drugs as a flavored syrup. It is another object of the present invention to pro Unfortunately, flavoring merely masks the unpleasant vide a method for administering medicaments for chil mouth taste but affects the palatability only slightly. A dren in a manner which will be platable to the child. number of medications have an especially bitter taste, 35 It is still another object of the present invention to and even adults reluctantly take them. In many such provide a method of administering medicaments in a cases even syrups cannot mask the bitter taste, thus solid form which may be chewed and then swallowed constituting a difficult pharmaceutical problem. without release of medicament in the mouth. Among the flavorings which have been used for the It is still a further object of the present invention to purpose of masking is chocolate. Examples of patents in provide such a method in which the medicament is not which chocolate is used in conjunction with medica released in the stomach but which passes through the ments, are U.S. Pat. Nos. 4,271,142 and 4,327,077 to stomach at substantially the speed of a liquid. Puglia et al, U.S. patent No. 3,697,641 to Ahrens, U.S. These and other objects are obtained in accordance Pat. No. 199,139 to Clark, British Pat. No. 543,309 to with the present invention by microencapsulating the Evans and Australian Pat. No. 7310/32 to Jones et al. 45 drug to be administered and embedding the microcap Children's vitamins encased in chocolate are also sules in a soft, sweet palatable matrix, such as chocolate. known and on the market, but in these products some of The combination of encapsulation of the drug and the the vitamins are not sufficiently stable. Laxatives in use of the soft, sweet matrix, such as chocolate, achieves chocolate are also well known. In all of these, however, the goals of both preventing the unpleasant taste which the unpleasant taste is merely masked and the medicines 50 the drugs may possess and overcoming the palatability still adversely affect the flavor of the chocolate and the problem that may arise when one tries to ingest the drug palatability of the medicine is not substantially im itself. The encapsulation will prevent the unpleasant proved. Furthermore, stability problems caused by di taste which many drugs possess and the chocolate ma rect contact of the drug with the chocolate can arise. trix will serve as a way to overcome the palatability In order to permit the release of orally administered 55 problem. Furthermore, the encapsulation will prevent drugs within selected portions of the alimentary canal, the medication from giving an off-flavor to the choco i.e., the stomach or intestine, pills in which the medica late itself, which inevitably occurs when drugs are ment are protected with a desired coating have been mixed directly with a chocolate matrix without first developed. A more advanced pharmaceutical form for being microencapsulated.
Load more

Recommended publications
  • The Effects of Intravenously Infused Vasodilators on the Renal Plasma Flow and Renal Tubules
    THE KURUME MEDICAL JOURNAL 1976 Vol.23, No.3, p.121-127 THE EFFECTS OF INTRAVENOUSLY INFUSED VASODILATORS ON THE RENAL PLASMA FLOW AND RENAL TUBULES YOON-YOUNG KIM Department of Pharmacology, Chung-ang University College of Medicine, Seoul, Korea (Received for publication July 29, 1976, introduced by Dr. M. Shingu) Nitroglycerin increased the renal plasma flow and altered electrolyte excretion. Perhexiline, i. v., caused an increase in sodium, chloride and osmolar clearance without the changes in the renal plasma flow. An eleva- tion of the tubular sodium rejection fraction probably contributed to the increased solute clearance. I soproterenol caused retention of sodium, chloride potassium, and water without changing the renal plasma flow or the glomerular filtration rate. The tubular rejection fraction of sodium was decreased, indicating that isoproterenol was directly increasing the tubular reabsorption. The renal changes induced by isoproterenol were not altered by pretreatment with perhexiline. INTRODUCTION In this study we selected two proto types of coronary vasodilators : nitro- Drugs which dilate the coronary glycerin and perhexiline HCl. The phar- arteries also affect other vascular beds. macological properties of perhexiline Since coronary vasodilators are pre- have been reported before (Cho et al., scribed for long periods of time, this 1970; Matsuo et al., 1970). Briefly, it effect on renal function and vasculature possess similar, as well as dissimilar, is an important consideration. We have pharmacological properties to that of reported previously on the unexpected nitroglycerin. Like nitroglycerin, per- effects of hexobendine on renal function hexiline is a coronary vasodilator and (Cho et al., 1973). Hexobendine is a its anti-anginal efficacy is currently portent coronary vasodilator whose bio-.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug
    USOO544607OA United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug. 29, 1995 54 COMPOST ONS AND METHODS FOR 4,659,714 4/1987 Watt-Smith ......................... 514/260 TOPCAL ADMNSTRATION OF 4,675,009 6/1987 Hymes .......... ... 604/304 PHARMACEUTICALLY ACTIVE AGENTS 4,695,465 9/1987 Kigasawa .............................. 424/19 4,748,022 5/1988 Busciglio. ... 424/195 75 Inventor: Juan A. Mantelle, Miami, Fla. 4,765,983 8/1988 Takayanagi. ... 424/434 4,789,667 12/1988 Makino ............ ... 514/16 73) Assignee: Nover Pharmaceuticals, Inc., Miami, 4,867,970 9/1989 Newsham et al. ... 424/435 Fla. 4,888,354 12/1989 Chang .............. ... 514/424 4,894,232 1/1990 Reul ............. ... 424/439 * Notice: The portion of the term of this patent 4,900,552 2/1990 Sanvordeker .... ... 424/422 subsequent to Aug. 10, 2010 has been 4,900,554 2/1990 Yanagibashi. ... 424/448 disclaimed. 4,937,078 6/1990 Mezei........... ... 424/450 Appl. No.: 112,330 4,940,587 7/1990 Jenkins ..... ... 424/480 21 4,981,875 l/1991 Leusner ... ... 514/774 22 Filed: Aug. 27, 1993 5,023,082 6/1991 Friedman . ... 424/426 5,234,957 8/1993 Mantelle ........................... 514/772.6 Related U.S. Application Data FOREIGN PATENT DOCUMENTS 63 Continuation-in-part of PCT/US92/01730, Feb. 27, 0002425 6/1979 European Pat. Off. 1992, which is a continuation-in-part of Ser. No. 0139127 5/1985 European Pat. Off. 813,196, Dec. 23, 1991, Pat. No. 5,234,957, which is a 0159168 10/1985 European Pat.
    [Show full text]
  • ATP Is Released Into the Rabbit Eye by Antidromic Stimulation of the Trigeminal Nerve
    ATP is released into the rabbit eye by antidromic stimulation of the trigeminal nerve Eugenio Maul and Marvin Sears Antidromic stimulation of the trigeminal nerve produces an irritative response in the rabbit eye characterized by ipsilateral miosis, hyperemia, elevated intraocular pressure, and a disruption of the blood-aqueous barrier. The latter is a bilateral effect. The mediator or mediators in- volved in this response of the eye are unknown. Increased ATP levels in aqueous humor could be found after trigeminal stimulation. Treatment of rabbits with dipyridamole further in- creased ATP levels in aqueous humor after stimulation, confirming the findings of Holton that stimulation of sensory nerves causes a release of ATP. Intravitreal injections of ATP could not reproduce the ocular irritative response; however, an iridial hyperemia of long latency and an increase in aqueous humor protein levels were produced. The mechanism of this part of the reaction requires further study. Key words: adenosine triphosphate, trigeminal nerve, aqueous humor, antidromic stimulation, irritative response, ocular hyperemia, dipyridamole Antidromic stimulation of the trigeminal mitter receptor mechanism.4 The substance nerve produces an irritative response in the or substances released by trigeminal nerve rabbit eye characterized by ipsilateral miosis, stimulation have not been identified. The hyperemia of the iris and conjunctiva, in- purpose of this study was to learn whether traocular hypertension, and a disruption of adenosine triphosphate (ATP) is released into the blood-aqueous, barrier.u 2 This last effect the rabbit eye by trigeminal nerve endings is also present in the contralateral eye.3 after antidromic stimulation and whether The irritative response produced by stimu- ATP could stimulate an irritative response.
    [Show full text]
  • The Antiepileptic Potential of Nucleosides
    Send Orders for Reprints to [email protected] Current Medicinal Chemistry, 2014, 21, 1-34 1 The Antiepileptic Potential of Nucleosides ,1 2,3 2 4,5 Z. Kovács* , K.A. Kékesi , G. Juhász and Á. Dobolyi 1Department of Zoology, University of West Hungary, Savaria Campus, Szombathely, Hungary; 2Laboratory of Pro- teomics, Institute of Biology, Eötvös Loránd University, Budapest, Hungary; 3Department of Physiology and Neurobiol- ogy, Eötvös Loránd University, Budapest, Hungary; 4Semmelweis University and the Hungarian Academy of Sciences, Department of Anatomy, Histology and Embryology, Neuromorphological and Neuroendocrine Research Laboratory Budapest, Hungary; 5Laboratory of Molecular and Systems Neuroscience, Institute of Biology, Eötvös Loránd Univer- sity and the Hungarian Academy of Sciences, Budapest, Hungary Abstract: Despite newly developed antiepileptic drugs to suppress epileptic symptoms, approximately one third of pa- tients remain drug refractory. Consequently, there is an urgent need to develop more effective therapeutic approaches to treat epilepsy. A great deal of evidence suggests that endogenous nucleosides, such as adenosine (Ado), guanosine (Guo), inosine (Ino) and uridine (Urd), participate in the regulation of pathomechanisms of epilepsy. Adenosine and its ana- logues, together with non-adenosine (non-Ado) nucleosides (e.g., Guo, Ino and Urd), have shown antiseizure activity. Adenosine kinase (ADK) inhibitors, Ado uptake inhibitors and Ado-releasing implants also have beneficial effects on epi- leptic seizures. These results suggest that nucleosides and their analogues, in addition to other modulators of the nucleo- side system, could provide a new opportunity for the treatment of different types of epilepsies. Therefore, the aim of this review article is to summarize our present knowledge about the nucleoside system as a promising target in the treatment of epilepsy.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Use of Uridine in Combination with Choline for the Treatment of Memory
    (19) TZZ ¥ __T (11) EP 2 322 187 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/7072 (2006.01) A61K 31/14 (2006.01) 14.05.2014 Bulletin 2014/20 A61K 31/685 (2006.01) A61P 25/28 (2006.01) (21) Application number: 10075660.0 (22) Date of filing: 30.07.1999 (54) Use of uridine in combination with choline for the treatment of memory disorders Verwendung von Uridin in Kombination mit Cholin zur Behandlung von Gedächtnisstörungen Utilisation de l’uridine en combinaison avec la choline pour le traitement des maladies de la mémoire (84) Designated Contracting States: (56) References cited: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU WO-A-97/45127 CH-A5- 680 334 MC NL PT SE DE-A1- 2 508 474 DE-A1- 2 629 845 DE-U1- 9 412 374 US-A- 4 221 784 (30) Priority: 31.07.1998 US 95002 P US-A- 4 994 442 US-A- 5 567 689 US-A- 5 700 590 (43) Date of publication of application: 18.05.2011 Bulletin 2011/20 • CACABELOSR ET AL: "THERAPEUTIC EFFECTS OF CDP-CHOLINE IN ALZHEIMER’S DISEASE (62) Document number(s) of the earlier application(s) in COGNITION, BRAIN MAPPING, accordance with Art. 76 EPC: CEREBROVASCULAR HEMODYNAMICS, AND 09173495.4 / 2 145 627 IMMUNE FACTORS", ANNALS OF THE NEW 07116909.8 / 1 870 103 YORK ACADEMY OF SCIENCES, NEW YORK 99937631.2 / 1 140 104 ACADEMY OF SCIENCES, NEW YORK, NY, US, 1 January 1996 (1996-01-01), pages 399-403, (73) Proprietor: Massachusetts Institute of Technology XP008065562, ISSN: 0077-8923 Cambridge, Massachusetts 02142-1601 (US) • SPIERS P A ET AL: "CITICOLINE IMPROVES VERBAL MEMORY IN AGING", ARCHIVES OF (72) Inventors: NEUROLOGY, AMERICAN MEDICAL • Watkins, Carol ASSOCIATION, CHICAGO, IL, US, vol.
    [Show full text]
  • Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2020 Anatomical Classification Guidelines V2020 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2020 Anatomical Classification Guidelines V2020 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 35 D DERMATOLOGICALS 50 G GENITO-URINARY SYSTEM AND SEX HORMONES 57 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 65 J GENERAL ANTI-INFECTIVES SYSTEMIC 69 K HOSPITAL SOLUTIONS 84 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 92 M MUSCULO-SKELETAL SYSTEM 102 N NERVOUS SYSTEM 107 P PARASITOLOGY 118 R RESPIRATORY SYSTEM 120 S SENSORY ORGANS 132 T DIAGNOSTIC AGENTS 139 V VARIOUS 141 Anatomical Classification Guidelines V2020 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn Et Al
    US 2003.0068365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn et al. (43) Pub. Date: Apr. 10, 2003 (54) COMPOSITIONS AND METHODS FOR Related U.S. Application Data ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME BEADS (60) Provisional application No. 60/327,643, filed on Oct. 5, 2001. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); Tanusin Ploysangam, Bangkok (TH); Publication Classification Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok (51) Int. Cl." .......................... A61K 9/127; A61K 35/78 (TH); Nardo Zaias, Miami Beach, FL (52) U.S. Cl. ............................................ 424/450; 424/725 (US) (57) ABSTRACT Correspondence Address: Law Office of Eric G. Masamori Compositions and methods for administration of active 6520 Ridgewood Drive agents encapsulated within liposome beads to enable a wider Castro Valley, CA 94.552 (US) range of delivery vehicles, to provide longer product shelf life, to allow multiple active agents within the composition, (21) Appl. No.: 10/264,205 to allow the controlled use of the active agents, to provide protected and designable release features and to provide (22) Filed: Oct. 3, 2002 Visual inspection for damage and inconsistency. US 2003/0068365A1 Apr. 10, 2003 COMPOSITIONS AND METHODS FOR toxic degradation of the products, leakage of the drug from ADMINISTRATION OF ACTIVE AGENTS USING the liposome and the modifications of the Size and morphol LPOSOME BEADS ogy of the phospholipid liposome vesicles through aggre gation and fusion. Liposome vesicles are known to be CROSS REFERENCE TO OTHER thermodynamically relatively unstable at room temperature APPLICATIONS and can Spontaneously fuse into larger, leSS Stable altered liposome forms.
    [Show full text]
  • Review of Existing Classification Efforts
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.1.1 Review of existing classification efforts Due date of deliverable: (15.01.2008) Actual submission date: (07.02.2008) Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UGent Revision 1.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public X PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) Task 4.1 : Review of existing classification efforts Authors: Kristof Pil, Elke Raes, Thomas Van den Neste, An-Sofie Goessaert, Jolien Veramme, Alain Verstraete (Ghent University, Belgium) Partners: - F. Javier Alvarez (work package leader), M. Trinidad Gómez-Talegón, Inmaculada Fierro (University of Valladolid, Spain) - Monica Colas, Juan Carlos Gonzalez-Luque (DGT, Spain) - Han de Gier, Sylvia Hummel, Sholeh Mobaser (University of Groningen, the Netherlands) - Martina Albrecht, Michael Heiβing (Bundesanstalt für Straßenwesen, Germany) - Michel Mallaret, Charles Mercier-Guyon (University of Grenoble, Centre Regional de Pharmacovigilance, France) - Vassilis Papakostopoulos, Villy Portouli, Andriani Mousadakou (Centre for Research and Technology Hellas, Greece) DRUID 6th Framework Programme Deliverable D.4.1.1. Revision 1.0 Review of Existing Classification Efforts Page 2 of 127 Introduction DRUID work package 4 focusses on the classification and labeling of medicinal drugs according to their influence on driving performance.
    [Show full text]
  • Adenosine Release and Functional Hyperemia in an Isolated Guinea Pig Heart Preparation
    ADENOSINE RELEASE AND FUNCTIONAL HYPEREMIA IN AN ISOLATED GUINEA PIG HEART PREPARATION by Gerard Ho 1mes Submitted to the Faculty of the School of Graduate Studies of the Medical College of Georgia in Partial Fulfillment of the Requirements for the. Degree of Doctor of Philosophy December 1983 ADENOSINE RELEASE AND FUNCTIONAL HYPEREMIA IN AN ISOLATED GUINEA PIG HEART PREPARATION This dissertation submitted by Gerard Holmes has been examined and approved by an appointed committee of the faculty of the School of G·raduate Studies of the Medical College of Georgia. The si-gnatures which appear below verify the fact that all required changes have been incorporated and that the dissertation has received final approval with reference to content, form and accuracy of presentation. This dissertation is therefore accepted in partial fulfillment of the requirements for the degree of Doctor of Philosophy. May 18, 1984 Date ACKNOWLEDGEMENTS The author wishes to express his sincerest appreciation to the members of his dissertation committee for their valued suggestions and to Dr. V.T. Wiedmeier for his advice, support and confidence, without which his dissertation would not have been pqssible. Special thanks go to Mrs.· E.J. Jones for her expert·technical assistance and for sharing her irrepres­ s i b1 e sense of human dignity. Finally the author a 1so wishes to thank the faculty of the School of Graduate Studies for their help in the construction of a sound foundation in the basic sciences and t.o his friends and family for their encouragement during difficult times. iii TABLE OF CONTENTS Page I.
    [Show full text]